The ClonoSIGHT test utilizes the company’s proprietary LymphoSIGHT technology, which works by sequencing DNA signatures that are present in immune cells to allow tracking of malignant sub-populations even when they are present at levels as low as one cell per million white blood cells.

Having shown to offer unprecedented sensitivity for the detection of residual cancer cells in marrow or blood, the test can be used to better measure a patient’s risk of post-treatment relapse and guide subsequent care, claims the company.

Using Sequenta’s CLIA-certified laboratory, the results from the test can be generated in seven days.

Sequenta chief scientific officer Malek Faham said the LymphoSIGHT platform has been validated in more than 10 clinical trials in the last year.

"These studies have demonstrated not only the technical improvements in sensitivity and specificity of the ClonoSIGHT test, but also the relevance of its performance for patient prognosis in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)," Faham added.

The company has also announced that the larger studies including prospective studies, conducted by oncology cooperative groups, are currently underway to extend the validation of the test.